Sciclone Pharma (SCLN) Misses Q4 EPS by 7c; Issues Weak FY14 EPS Outlook
Tweet Send to a Friend
Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) reported Q4 EPS of $0.08, $0.07 worse than ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
